Treatment of chronic renal allograft rejection in rats with a low-molecular-weight heparin (reviparin)

Transplantation

Volumn 72, Issue 2, 2001, Pages 209-215

  Braun, Claude ^a   Schultz, Melanie ^a   Fang, Liu ^a   Schaub, Meike ^a   Back, Walter E ^a   Herr, Dieter ^b   Laux, Volker ^b   Rohmeiss, Peter ^a   Schnuelle, Peter ^a   Van Der Woude, Fokko J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Knoll AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; REVIPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HISTOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; LONG TERM CARE; LYMPHOCYTIC INFILTRATION; MALE; MONOCYTE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT;

EID: 0034899069     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200107270-00007     Document Type: Article

References (61)

1. Chronic transplant rejection
2. Chronic graft rejection
3. Both alloantigen-dependent and -independent factors influence chronic allograft rejection
4. Chronic allograft rejection
5. Prevention of functional, structural, and molecular changes of chronic rejection of rat renal allografts by a specific macrophage inhibitor
6. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism
7. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts
8. Improvement of chronic renal allograft rejection in rats with the oral endothelin A-receptor antagonist LU135252
9. Studies on experimental hetero-immune nephritis. II. Prevention by immunosuppressive agents and certain anticoagulants
10. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins
11. Inhibition of T lymphocyte heparanase by heparin prevents cell migration and cell-mediated immunity
12. The effects of orally administered calcium pentosan polysulfate on inflammation and cartilage degradation produced in rabbit joints by intraarticular injection of a hyaluronate-polylysine complex
13. Heparin inhibits mesangial cell proliferation in habu-venom-induced giomerular injury
14. Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis
15. The semisynthetic polysaccharide pentosan polysulfate prevents complement-mediated injury in the rabbit perfused heart
16. Heparin protects cultured endothelial cells from damage by toxic oxygen metabolites
17. Protective effect of dextran sulfate and heparin on adult rat cardiomyocytes damaged by free radicals
18. Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury
19. Effects of heparin and N-acetylheparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart
20. Oral delivery of low molecular weight heparin in rat cardiac allografts
21. Prolongation of rat skin and cardiac allograft survival by low molecular weight heparin
22. Increased rat cardiac allograft survival by the glycosaminoglycan pentosan polysulfate
23. Low dose heparin: Efficacious treatment for chronic renal allograft rejection
24. Pharmacological profile of reviparin-sodium
25. Reviparin-sodium prevents complement-mediated myocardial injury in the isolated rabbit heart
26. Biochemical and pharmacological characteristics of reviparin, a low-molecular-mass heparin
27. Progressive albuminuria and glomerulosclerosis in a rat model of chronic renal allograft rejection
28. An improved technique of renal transplantation in the rat
29. Report of the third Banff conference on renal allograft pathology (July 20-24, 1995) on classification and lesion scoring in renal allograft pathology
30. Role of heparin as a protective agent following reduction of renal mass
31. N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation
32. Non-anticoagulant protective effect of heparin in chronic aminonucleoside nephrosis
33. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy
34. Effect of low molecular weight heparin on suppression of chronic graft vascular disease in a rat cardiac allograft model
35. Sulfation-dependent down-regulation of interferon-gamma-induced major histocompatibility complex class I and II and intercellular adhesion molecule-1 expression on tubular and endothelial cells by glycosaminoglycans
36. Antihypertensive drug treatment in chronic renal allograft rejection in the rat
37. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass
38. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression
39. Heparin lowers the blood pressure in hypertensive rats
40. Heparin lowers blood pressure: Biological and clinical perspectives
41. Reduction of myocardial infarct size and reperfusion by the glycosaminoglycan pentosan polysulfate
42. LU 51198, a highly sulfated, low-molecular-weight heparin derivative, prevents complement-mediated myocardial injury in the perfused rabbit heart
43. Heparin treatment reduces glomerular injury in rats with adriamycin-induced nephropathy but does not modify tubulointerstitial damage or the renal production of transforming growth factor-beta
44. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria
45. Angiotensin stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular cells
46. Angiotensin and endothelin in chronic glomerulonephritis
47. Heparin suppresses endothelin-1 action and production in spontaneously hypertensive rats
48. Heparin disaccharides inhibit tumor necrosis factor-α production by macrophages and arrest immune inflammation in rodents
49. Binding of interferon gamma to heparan sulphate is restricted to the heparin-like domains and involves carboxylic but not N-sulphated-groups
50. Growth factors in the extracellular matrix
51. Characterization of human recombinant interleukin 2 binding to heparin and heparan sulfate using an ELISA approach
52. Interleukin-5 binds to heparin/heparan sulfate. A model for an interaction with extracellular matrix
53. Identification of a glycosaminoglycan binding surface on human interleukin-8
54. IL-12 is a heparin-binding cytokine
55. Structure and function of the glycosaminoglycan binding site of chemokine macrophage-inflammatory protein-1 beta
56. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation
57. Downregulation of class II antigen expression by FGF-heparin complexes is due primarily to heparin effect
58. Cytokine gene expression in human LPS- and IFNgamma-stimulated mononuclear cells is inhibited by heparin
59. Mesangial cell turnover: Effect of heparin and peptide growth factors
60. Pentosan polysulfate decreases proliferation and net extracellular matrix production in mouse mesangial cells
61. Inhibition of rat mesangial cell growth by heparan sulfate